Click image to enlarge
The
V-PLEX platform offers analytically validated singleplex and multiplex assay kits. Developed under rigorous design control, V-PLEX kits provide accurate and reproducible results with consistency from lot to lot. The V-PLEX Angiogenesis Panel 1 (human) Kit includes seven biomarkers that are associated with cardiovascular diseases (Table 1). The assays can be used for quantitative measurements in the sample types listed in the “Specifications” tab below and offer detection limits (LLODs and LLOQs) in the sub- to low pg/mL range.
| Analyte | LLOD | LLOQ | ULOQ | Dynamic Range | Unit | | FGF (basic) | 0.09 | 2.6 | 1,780 | 0.09 - 1,780 | pg/mL |
| PlGF | 0.21 | 1.5 | 800 | 0.21 - 800 | pg/mL |
| Tie-2 | 31.3 | 396 | 63,400 | 31.3 - 63,400 | pg/mL |
| VEGF-A | 0.4 | 5 | 1510 | 0.40 - 1,510 | pg/mL |
| VEGF-C | 9.91 | 146 | 17,500 | 9.91 - 17,500 | pg/mL |
| VEGF-D | 4.36 | 67.1 | 18,800 | 4.36 - 18,800 | pg/mL |
| VEGFR-1/Flt-1 | 0.9 | 10 | 6,410 | 0.90 - 6,410 | pg/mL |
|
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Application(s)
|
|
Cardiovascular
,
Growth Factors
|
|
|
Analyte(s)
|
|
FGF (basic), PlGF, Tie-2, VEGF-A, VEGF-C, VEGF-D, VEGFR-1/Flt-1
|
|
|
Species
|
|
Human
|
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
MESO SECTOR S 600MM
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120MM
,
MESO QuickPlex SQ 120
,
MESO SECTOR S 600
|
|
|
Plate Type
|
|
96-well
|
|
|
Sample Type
|
|
Serum, EDTA Plasma, Urine, Cell Culture Supernatant, Cell Lysate
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
≤-70 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
SULFO-TAG Human VEGF Antibody
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
Angiogenesis Panel 1 (human) Plate
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
Diluent Assembly 11 (includes Diluent 7 – 50 mL, Diluent 11 – 5 mL)
|
≤-10 °C
|
1 each
|
|
|
|
|
RT
|
1 bottle
(50 mL)
|
|
|
|
MSD Blocker A
|
RT
|
1 bottle
(250 mL)
|
|
|
|
MSD Phosphate Buffer
5X
|
RT
|
1 bottle
(50 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
≤-70 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
SULFO-TAG Human VEGF Antibody
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
Angiogenesis Panel 1 (human) Plate
|
2-8 °C
|
5 each
(1 each)
|
|
|
|
Diluent Assembly 12 (includes Diluent 7 – 50 mL, Diluent 11 – 50 mL)
|
≤-10 °C
|
1 each
|
|
|
|
|
RT
|
1 bottle
(50 mL)
|
|
|
|
MSD Blocker A
|
RT
|
1 bottle
(250 mL)
|
|
|
|
MSD Phosphate Buffer
5X
|
RT
|
1 bottle
(50 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
≤-70 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
SULFO-TAG Human VEGF Antibody
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
Angiogenesis Panel 1 (human) Plate
|
2-8 °C
|
25 each
(1 each)
|
|
|
|
Diluent Assembly 12 (includes Diluent 7 – 50 mL, Diluent 11 – 50 mL)
|
≤-10 °C
|
5 each
|
|
|
|
|
RT
|
5 bottle
(50 mL)
|
|
|
|
MSD Blocker A
|
RT
|
5 bottle
(250 mL)
|
|
|
|
MSD Phosphate Buffer
5X
|
RT
|
5 bottle
(50 mL)
|
|
|
|
Product Inserts
|
|
|
|
Datasheets
|
|
|
|
Certificate of analysis
|
|
View More
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
|
|
|
|
Plasma-Derived Inflammatory Proteins Predict Oral Squamous Cell Carcinoma
|
|
|
|
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial
|
|
|
|
A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study.
|
|
|
|
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2 in patients with advanced hepatocellular cancer.
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters